The Board of Directors has in-depth knowhow in drug development in the pharmaceutical and biotech industry.
Roger M Nitsch is a Founder and President of Neurimmune. A neuroscientist with a background in medicine, Roger M Nitsch is recognized as a key opinion leader in neurodegenerative disease research with more than 20 years of experience in Alzheimer’s disease research, and as a pioneer of disease-modifying therapeutic approaches for neurodegenerative diseases. The Potamkin prize winner, and Member of the German Academy of Sciences, directs the Institute for Regenerative Medicine (IREM) at the University of Zurich, Switzerland.
Jan Grimm is a neuroscientist with 15 years of experience in drug discovery and development in US and European biotech. Dr. Grimm co-founded Neurimmune in 2006 and served as the company's founding CEO. Before joining Neurimmune he led the Alzheimer’s disease research efforts at Rinat Neuroscience Corp. in San Francisco that was acquired by Pfizer in 2006. He received his PhD from Max Delbrück Center for Molecular Medicine and Humboldt University Berlin.
Christoph Hock co-founded Neurimmune in 2006 and served from the beginning as board member. Prof. Hock is the co-director of the Institute of Regenerative Medicine (IREM) at the University of Zurich, Switzerland. As a clinican and clinical trials investigator, Prof. Hock has directed more than 30 clinical trials and is an internationally recognized expert on clinical Alzheimer's disease translational medicine approaches. He was member of the Research Council of the Swiss National Science Foundation. Christoph Hock has been elected as Vice President for Medicine and Science at University of Zurich and took office on February 1, 2015 for an initial 18-month term. During this period his Board mandate remains dormant.